Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide responsive chronic pulmonary GVHD

C J Forsyth1, P D Cremer, P Torzillo

  • 1Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Bone Marrow Transplantation
|February 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Late Relapses in Hodgkin's Disease: Are They a Distinct Entity?

Leukemia & lymphoma·2016
Same author

Rapid Screening of Mutant N-ras Alleles by Analysis of PCR-Induced Restriction Sites: Allele Specific Restriction Analysis (ASRA).

Leukemia & lymphoma·2016
Same author

Amino acids and the kidney.

Amino acids·2013
Same author

D-Amino acids in chronic renal failure and the effects of dialysis and urinary losses.

Amino acids·2013
Same author

Leukaemias into the 21st century. Part 2: the chronic leukaemias.

Internal medicine journal·2013
Same author

Inflammatory trigeminal nerve and tract lesions associated with inferior alveolar nerve anaesthesia.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2013
Same journal

Transplant outcomes for patients with severe acquired aplastic anemia over the age of 40 using busulfan, fludarabine, reduced-dose cyclophosphamide, and anti-thymocyte globulin conditioning regimen.

Bone marrow transplantation·2026
Same journal

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same journal

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026
Same journal

Evaluation of a novel eHealth-facilitated, post HCT-integrated care model on implementation and rehospitalization: results from the Swiss SMILe hybrid-RCT.

Bone marrow transplantation·2026
Same journal

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Bone marrow transplantation·2026
Same journal

A multimodal sexual health intervention among hematopoietic stem cell transplant recipients: mediating effects on quality of life and mood.

Bone marrow transplantation·2026
See all related articles

Thalidomide significantly improved lung function in a patient with severe chronic pulmonary graft-versus-host disease (GVHD) after bone marrow transplant. This improvement persisted even after discontinuing thalidomide, offering a new therapeutic option for GVHD.

Area of Science:

  • Hematology
  • Immunology
  • Pulmonology

Background:

  • Allogeneic bone marrow transplantation is a curative option for multiple myeloma.
  • Pulmonary graft-versus-host disease (GVHD) is a serious complication following transplantation.
  • Standard treatments for chronic pulmonary GVHD, including immunosuppressants, often show limited efficacy.

Observation:

  • A patient with progressive multiple myeloma received allogeneic bone marrow transplantation.
  • Post-transplant, the patient developed severe chronic pulmonary GVHD refractory to standard therapies (cyclosporin A, corticosteroids, azathioprine).

Findings:

  • Introduction of thalidomide led to a remarkable recovery of lung function.
  • The positive effect on pulmonary function was sustained long-term, even after thalidomide withdrawal.

Related Experiment Videos

  • The patient remained clinically stable 40 months post-transplantation.

    • Implications:

    • Thalidomide represents a promising therapeutic strategy for refractory chronic pulmonary GVHD.
    • This case highlights the potential of thalidomide in managing severe GVHD complications.
    • Further research into thalidomide's mechanism in GVHD is warranted.